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Abstract
The mechanism by which trauma initiates healing remains unclear.
Precise understanding of these events may define interventions for
accelerating healing that could be translated to the clinical arena.
We previously reported that addition of low-dose recombinant
human TNF (rhTNF) at the fracture site augmented fracture repair
in a murine tibial fracture model. Here, we show that local rhTNF
treatment is only effective when administered within 24 h of
injury, when neutrophils are the major inflammatory cell infiltrate.
Systemic administration of anti-TNF impaired fracture healing.
Addition of rhTNF enhanced neutrophil recruitment and promoted
recruitment of monocytes through CCL2 production. Conversely,
depletion of neutrophils or inhibition of the chemokine receptor
CCR2 resulted in significantly impaired fracture healing. Fragility,
or osteoporotic, fractures represent a major medical problem as
they are associated with permanent disability and premature
death. Using a murine model of fragility fractures, we found that
local rhTNF treatment improved fracture healing during the early
phase of repair. If translated clinically, this promotion of fracture
healing would reduce the morbidity and mortality associated with
delayed patient mobilization.
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Introduction
Bone fractures are a very common clinical problem affecting of
3.6% of the UK population every year (Donaldson et al, 2008).
While the majority of fractures heal uneventfully, they are particu-
larly problematic in certain subgroups of patients, including high-
energy open fractures which represent limb-threatening injuries
prone to delayed and non-union, and fractures in osteoporotic
bone, which represent the greatest unmet clinical need. Although
addition of exogenous bone morphogenetic proteins (BMPs) results
in improved healing in animal models, clinical trials of BMPs for
tibial non-union (Friedlaender et al, 2001) and fracture healing
(Govender et al, 2002) have failed to achieve the efficacy antici-
pated (Lane, 2001; Lieberman et al, 2002). This is probably because
a single supraphysiological dose of BMP does not induce the
complex pattern of growth factor and cytokine production required
for optimal fracture repair. Currently, there is no approved therapy
to enhance healing of fragility fractures in osteoporotic bone
(Kanakaris et al, 2009). Antibodies to endogenous inhibitors of the
Wnt/b-catenin signaling pathway, including sclerostin and dick-
kopf-1, have shown early promise but are limited to systemic
administration, leading to non-specific bone deposition. Further-
more, these are associated with safety concerns, including carcino-
genesis and closure of osteal foramina (Baron & Hesse, 2012).
Therefore, there is an urgent unmet medical need to develop thera-
peutic strategies to improve local bone regeneration and the healing
of fractures.
The ideal biological therapy for accelerating fracture healing
would entail local administration of pro-osteogenic factor(s) at the
time of surgical treatment. Therefore, it is critical to understand
how the early inflammatory response initiates and orchestrates frac-
ture repair, an area that remains poorly understood. A competent
immune system is essential for effective wound healing, although
excessive inflammation has been found to be deleterious. For
example, the absence of TNF or IL-6 signaling has been found to
impair fracture healing (Gerstenfeld et al, 2003a; Yang et al, 2007),
whereas persistent and elevated levels of TNF in rheumatoid arthri-
tis are associated with bone destruction (Binder et al, 2013) and
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systemic daily administration of high-dose TNF in a rat rib fracture
model also resulted in impaired healing (Hashimoto et al, 1989).
Therefore, there is a critical balance to ensure an optimal healing
environment (Chan et al, 2012c).
It is currently unknown how early inflammation initiates the
process of fracture healing. We have previously shown that
injection of low-dose rhTNF at the fracture site in a murine tibial
fracture model of endochondral healing led to improved callus
formation and earlier remodeling (Glass et al, 2011). This was in
part achieved through the recruitment and osteogenic differentia-
tion of mesenchymal stromal cells (MSCs) by TNF (Glass et al,
2011). Studies of early fracture hematoma by other groups have
shown that the inflammatory phase following fracture is critical to
recruit cells and orchestrate the events necessary for fracture
healing (Grundnes & Reikeras, 1993; Kolar et al, 2010, 2011; Hoff
et al, 2013).
Here, we describe the early fracture-healing pathway and the
enhancement of the early innate immune response by TNF adminis-
tration in the first 24 h after injury. Interventions targeting events
during this early time window should allow effective and simple
clinical translation, as the therapeutic would be administered at the
time of reduction and stabilization of the fractures.
Results
Local addition of TNF during early inflammatory phase augments
fracture repair in C57BL/6 mice
We previously reported that 1 ng rhTNF injected at the fracture site
on days 0 and 1 improved fracture repair (Glass et al, 2011). To
identify the optimal dose in vivo, we injected increasing amounts
of rhTNF at the fracture site on days 0 and 1 (i.e. immediately and
at 24 h) following osteotomy and found that rhTNF was effective
in augmenting fracture healing, as indicated by increased relative
% callus mineralization, by day 28 after injury only at 1 ng
(Fig 1A). As shown by the micro-CT reconstructions, treatment
with 1 ng of rhTNF led to improved healing and earlier remodeling
as evidenced by a more compact and mineralized fracture callus
(Fig 1D).
We also found that augmented fracture healing was only evident
when rhTNF at 1 ng was administered at the fracture site over the
first 24 h (Fig 1B). This would be particularly relevant for clinical
translation as this would enable treatment at the time of reduction
and stabilization of the fracture.
Inhibition of TNF impairs fracture repair in vivo
To confirm the role of TNF in fracture healing in vivo, we inhibited
endogenous TNF by either systemic administration of a neutralizing
antibody to TNF, TN3, or local injection of recombinant murine
IL-10 (rmIL-10), which also inhibits TNF expression and release
(Smallie et al, 2010), at the fracture site. As shown in Fig 1C, the
relative callus mineralization was reduced by both treatments at day
28. The micro-CT reconstructions showed that systemic anti-TNF
led to poor bridging across the fracture site and an incomplete and
poorly mineralized callus, whereas local rmIL-10 treatment led to a
large, unmineralized callus, the hallmarks of an immature callus
(Fig 1D). These observations are consistent with the augmented
callus maturation seen in mice treated with 1 ng of TNF.
TNF is expressed during the early inflammatory response by
innate immune cells
TNF is released as part of the early inflammatory response to the
bone injury as it is for other injuries and stresses (Kon et al, 2001)
and is an important mediator in fracture repair (Gerstenfeld et al,
2003a; Glass et al, 2011). However, the precise quantities, and
spatial and temporal sequences of release as well as its role in frac-
ture healing remain unclear. We found that circulating serum levels
of TNF did not differ significantly from no injury controls up to 72 h
post-fracture (Supplementary Fig S1A), indicating that the level of
trauma induced by the isolated tibial fracture in our murine model
is insufficient to lead to a systemic inflammatory response. To
assess the local cytokine environment at the fracture site, murine
fracture supernatants were produced by incubating fractured tibiae
in media as described previously (Glass et al, 2011). Consistent with
our published findings in human fracture supernatants (Glass et al,
2011), the levels of TNF were very low (< 2 pg/ml, the level of
detection of the MSD chemiluminescent system).
Our observation that TNF inhibition impaired fracture healing
in vivo suggests that endogenous TNF is expressed locally, albeit at
a low level. Hence, we employed in situ hybridization on histologi-
cal sections of the murine fracture site (Fig 1E–G) to enable identifi-
cation of the cellular sources of TNF in vivo. We found that TNF
was expressed within 15 min of injury, co-localizing first with endo-
thelial cells and neutrophils (Fig 1F). The neutrophils were identi-
fied by their polymorphonuclear morphology as well as by positive
staining with anti-neutrophil elastase or anti-Ly6G (Fig 2B). From
day 3 onwards, TNF expression co-localized with cells of the
monocyte/macrophage lineage (F4/80+) (Fig 1G). Neutrophils were
the predominant cell type present before day 3 (at 3 h, 24 h, and
3 days) with no F4/80+ cells identified at this stage, while the latter
were the predominant cell type after day 3 (day 5 and day 7) as
shown by the representative sections in Fig 1G.
Neutrophil recruitment occurs following fracture and promotes
fracture repair
As recruitment of neutrophils represents a key early event during
the inflammatory response (Nathan, 2006), we investigated their
role in fracture healing. First, we assessed the systemic mobilization
of neutrophils in our murine fracture model. Blood neutrophil count
increased within 30 min of injury and peaked at 3 h following
fracture (Fig 2A).
Next, mice were treated with a validated and specific Ly6G-
blocking antibody (Daley et al, 2008). This effectively inhibited the
mobilization of neutrophils into the systemic circulation as well as the
local recruitment of neutrophils to the fracture site (Fig 2B and C).
Anti-Ly6G treatment was associated with significant impairment of
fracture healing. Representative histological section stained with
Masson’s trichrome at day 14 showed anti-Ly6G treatment led to
formation of a large immature and unmineralized callus compared
to IgG control treatment (Fig 2D). Anti-Ly6G treatment resulted in
delayed mineralization and remodeling of the fracture callus at day
28 (Fig 2E).
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Addition of rhTNF to the fracture environment promotes the
recruitment of neutrophils, monocytes, and CCL2 expression
Since rhTNF was only effective when given in the first 24 h follow-
ing injury and the major inflammatory cell infiltrate during this
period consisted primarily of TNF-expressing neutrophils, we inves-
tigated whether exogenous rhTNF, which led to augmented fracture
repair in vivo, acted via neutrophils. We hypothesized that addi-
tional rhTNF at the fracture site would enhance the innate immune
response to promote the recruitment of neutrophils, which in turn
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Figure 1. Role of TNF in fracture healing in vivo.
A Addition of rhTNF at the fracture site on days 0 and 1 led to augmented healing, indicated by increased % callus mineralization, at day 28 after operation in a dose-
dependent manner. Data are presented as mean  SEM. Treatment with 1 ng TNF versus PBS control, ****P < 0.0001 by one-way ANOVA with Dunnett’s multiple
comparisons test.
B Addition of rhTNF at the fracture site must be given within the first 24 h to augment healing, indicated by % callus mineralization. Data are presented as
mean  SEM. 1 ng TNF versus PBS control treatment on days 0 and 1, ***P = 0.0009 by one-way ANOVA with Dunnett’s multiple comparisons test.
C Treatment with systemic anti-TNF or local rmIL-10 led to impaired fracture repair at day 28, indicated by % callus mineralization. Data are presented as
mean  SEM. Treatment with PBS control versus anti-TNF, *P = 0.037, PBS control versus rmIL-10, *P = 0.037, by unpaired two-sided t-tests.
D Representative micro-CT images at the fracture site showing (from left to right): lateral view of tibia, cross-section, and cross and longitudinal sections with color
overlay and 3D reconstruction. In the color overlays, the shade of blue corresponds to percentage mineralization: light blue denotes soft immature callus, whereas
dark blue denotes hard mineralized callus. Scale bar, 2 mm.
E Representative ISH image (light field) showing TNF expression at the murine fracture site at 24 h after fracture. Scale bar, 250 lm. Red box indicates region of interest.
F High-power micrographs of region of interest from (E): at 24 h after fracture, mTNF expression (white signal on dark field, above) co-localized with
polymorphonuclear cells found on the adjacent H&E section (below). Scale bar, 25 lm. Neutrophils were identified by their polymorphonuclear morphology as well as
positive dark brown staining with anti-neutrophil elastase.
G High-power micrographs: at 7 days, TNF expression (white signal on dark field, above) co-localized with F4/80-positive cells (stained dark brown) extravasating from
a blood vessel on the adjacent H&E section (below). Scale bar, 25 lm.
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Figure 2. Role of neutrophils in fracture healing.
A Neutrophils were mobilized into the murine systemic circulation within 30 min of injury in our murine fracture model. Compared to control and number of blood
neutrophils at 3 h ***P = 0.0006 and at 6 h *P = 0.042, by one-way ANOVA with Dunnett correction.
B Depletion of neutrophils using anti-Ly6G. Intravenous anti-Ly6G treatment led to depletion of neutrophils in the systemic circulation (left) as well the local peri-
fracture soft tissues (right). Left: counts of neutrophils in the blood harvested by cardiac puncture at 3 h post-injury. Data are presented as mean  SEM
(**P = 0.0074 using unpaired one-tailed t-test). Right: counts of positively stained infiltrative neutrophils in the adjacent muscle to the fracture site comparing
neutrophil depletion with anti-Ly6G antibody versus IgG control at day 1 and day 7 post-fracture. At day 1, number of neutrophils in control group as detected by
Ly6G and NE in control versus treatment: ****P = 0.0001 for both Ly6G and NE, by unpaired two-tailed t-test. At day 7, number of neutrophils in control group as
detected by Ly6G and NE in control versus treatment groups: ****P = 0.0001 for Ly6G and *P = 0.020 for NE, by unpaired two-tailed t-test. Number of neutrophils at
day 1 versus day 7 in control groups, *P = 0.037 for Ly6G and ***P = 0.0006 for NE, by unpaired two-tailed t-test.
C Representative sections showing local infiltration of neutrophils in the adjacent muscle stained using anti-Ly6G and anti-neutrophil elastase primary antibodies at
day 1 post-fracture following treatment with anti-Ly6G antibody or IgG control. Scale bar, 100 lm.
D Depletion of neutrophils using anti-Ly6G led to impaired fracture healing. Representative section stained with Masson’s trichrome at day 14 comparing fracture
healing in mouse treated with isotype control (top) versus anti-Ly6G (bottom). Black and white images in the right column are identical to the color images in the left
column; they have been labeled to clearly demonstrate the anatomical structures. Control section shows advanced mineralized callus, while treatment section shows
a large immature unmineralized callus. Muscle fibers: red; collagen, bone, and mineralized callus: green. Scale bar, 1 mm.
E Anti-Ly6G treatment led to impaired fracture healing as shown by the reduced % callus mineralization at day 28 after surgery and representative micro-CT images.
Anti-Ly6G treatment led to delayed mineralization and remodeling of the fracture callus compared to control. Data are presented as mean  SEM. ***P = 0.0006 by
unpaired two-sided t-test. Scale Bar, 2 mm.
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attract monocytes that have been shown to be associated with frac-
ture healing (Alexander et al, 2011) and orchestrate wound healing
in other tissues (Scapini et al, 2000; Nathan, 2006; Soehnlein &
Lindbom, 2010). We found that anti-Ly6G treatment also depleted
the number of neutrophils and F4/80+ cells at the fracture site on
histology on days 0 and 7 (Figs 2B, C and 3A). The analysis of
numerous sections at multiple time points and the sacrifice of many
animals would be required to translate the static pictures provided
by histology into an appreciation of the dynamics of cell migration
and chemokine release in vivo. Therefore, we used the air pouch
model of inflammation, a widely accepted and validated in vivo
model for studying the regulation of the early events of local inflam-
mation (Romano et al, 1997; Lawrence et al, 2001), to accurately
quantify the neutrophils and monocytes attracted to the complex
local fracture cytokine milieu. Media or murine fracture supernatants
prepared as described above were injected into the air pouch either
alone or in combination with 1 ng rhTNF, and the cellular infiltrates
assessed at 4 h. Addition of rhTNF to fracture supernatant into the
air pouch resulted in an increase in both the numbers of neutrophils
(Ly6G+, CD11b+ cells) and monocytes/macrophages (Ly6G,
CD11b+, CD115+ cells) (Fig 3B and Supplementary Fig S1D).
As monocytes are recruited by chemokines during the inflamma-
tory response (Nathan, 2006; Soehnlein & Lindbom, 2010), we
examined the production of the key neutrophil-derived monocyte
chemokines CCL2 (MCP-1), CCL3 (MIP-a), and sIL-6R. Addition of
1 ng of rhTNF in the air pouches led to an increase in CCL2 levels
as determined by ELISA (Fig 3C), while levels of CCL3 and sIL-6R
were unaffected (Supplementary Fig S1C). The enhanced recruit-
ment of both neutrophils and F4/80+ cells into the air pouch model
by TNF was abrogated by the addition of CCL2 neutralizing anti-
body (Fig 3B). Representative FACS plots are shown in Supplemen-
tary Fig S1D.
To determine whether rhTNF can promote CCL2 expression by
murine neutrophils, we used enriched preparations of murine
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Figure 3. TNF promotes recruitment of innate immune cells and CCL2 expression.
A Anti-Ly6G treatment depletes local monocytes/macrophages at the fracture site. Counts of positively stained infiltrative F4/80+ cells in the adjacent muscle to the
fracture site following treatment with control or anti-Ly6G at day 1 and day 7. Data are presented as mean  SEM. **P = 0.005 at day 1 and **P = 0.002 at day 7,
and *P = 0.013 for control at day 1 versus control at day 7, by unpaired two-sided t-test.
B Addition of 1 ng rhTNF to fracture supernatant in the air pouch model led to increased numbers of neutrophils (Ly6G+, CD11b+ cells) and monocytes/macrophages
(Ly6G, CD11b+, CD115+ cells) in the cellular infiltrate. These effects were abrogated by the addition of anti-CCL2. Neutrophils: FS versus FS + TNF *P = 0.015,
FS + TNF versus FS + TNF + anti-CCL2 *P = 0.028, and FS + TNF + anti-CCL2 versus FS + TNF + IgG *P = 0.042 by one-way ANOVA followed by Bonferroni’s
multiple comparison test. Monocytes/macrophages: FS versus FS + TNF **P = 0.0063, FS + TNF versus FS + TNF + anti-CCL2 ****P < 0.0001, and FS + TNF + anti-
CCL2 v FS + TNF + IgG *P = 0.015 by one-way ANOVA followed by Bonferroni’s multiple comparisons test.
C Addition of 1 ng rhTNF to fracture supernatant increased CCL2 protein levels in the air pouch. “Neat” indicates level of CCL2 in fracture supernatant before injection
into air pouch. Data are presented as mean  SEM. FS versus FS + TNF **P = 0.0020 by one-way ANOVA with Bonferroni’s multiple comparisons test.
D Addition of rhTNF to enriched bone marrow-derived murine neutrophils pre-exposed to fracture supernatant in vitro led to up-regulation of CCL2 production at 1 h.
Data are presented as mean  SEM. No TNF versus TNF 0.01 ng/ml *P = 0.012, TNF 0.1 ng/ml ***P < 0.0001, TNF 1.0 ng ***P = 0.0001, TNF 10 ng/ml
***P < 0.0001, and TNF 100 ng/ml *P = 0.023 by one-way ANOVA with Dunnett’s multiple comparisons test.
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neutrophils derived from the tibiae of C57BL/6 mice (82.7%)
(Supplementary Fig S1E) and incubated them in fracture superna-
tant and rhTNF at a range of concentrations in vitro. Addition of
10 pg or more of rhTNF promoted CCL2 expression in neutrophils
at 1 h following exposure to fracture supernatant (Fig 3D).
There is controversy in the literature over whether neutrophils
are able to produce CCL2. It is possible that the CCL2 production
seen in Fig 2H may be attributed to contaminant cells other than
neutrophils. To determine the ability of murine neutrophils to
express CCL2, we used immunocytochemistry to detect co-
expression (merged signal: yellow/orange) of neutrophil elastase
(green) and CCL2 (red). We collected cells from murine whole
blood followed by red cell lysis. Neutrophils were identified by
the multi-lobulated morphology of their nuclei on DAPI (blue)
and the expression of neutrophil elastase. We then exposed the
cells to either control media or fracture supernatant for 30 min
followed by 1 ng rhTNF. Murine neutrophils derived from whole
blood clearly expressed CCL2 when exposed to a combination of
fracture supernatant and TNF, but not to TNF alone (Supplementary
Fig S1F).
CCR2 inhibition impairs fracture repair in vivo
The CCL2/CCR2 axis has been found to be important in the healing
response of other types of tissue, including skeletal muscle (Weber
et al, 1999; Surgeons AAoO, 2007; Martinez et al, 2010; Lu et al,
2011; Arefieva et al, 2012; Chan et al, 2012a; Chen et al, 2012;
Liang et al, 2012; Suresh et al, 2012; Wan et al, 2012; Kostarnoy
et al, 2013). In vivo inhibition of CCR2, the G-protein-coupled recep-
tor for CCL2, using small molecule inhibitor INCB3344 as previously
described (Brodmerkel et al, 2005; Shin et al, 2009; Xue et al, 2010)
significantly impaired endochondral fracture healing compared to
vehicle control at day 28 after surgery (Fig 4). The micro-CT recon-
structions show that CCR2 inhibition led to very poor fracture callus
formation, as evidenced by impairment of new bone formation and
lack of bridging across the fracture site (Marsh, 1998). However,
local administration of rmCCL2 at 10 and 100 ng at the fracture site
on days 0 and 1 did not affect fracture repair at day 28 on micro-CT
analysis (Supplementary Fig S1G), most likely due to suboptimal
pharmacodynamics including the short half-life of the protein and
pharmacodynamics (Ruggiero et al, 2003).
Addition of rhTNF augments fracture repair in osteoporotic mice
Osteoporotic fractures represent a huge unmet clinical need. We
rendered mice osteoporotic by ovariectomy (He et al, 2011)
(Supplementary Fig S1H). We then assessed the effect of TNF on
fracture healing in these animals. Treatment with 1 ng TNF at the
fracture site on days 0 and 1 led to an increased relative callus
mineralization at day 14 after surgery, but by day 28, healing was
equivalent to PBS-treated controls (Fig 5). This indicates that local
administration of rhTNF leads to initial accelerated healing to
achieve the same final result over a shorter period. The micro-CT
images show that rhTNF treatment led to mature callus bridging
across the fracture, which was absent in the PBS-treated control
group, at day 14.
Discussion
Fracture repair involves a complex cascade of events involving
numerous cell types and the spatially and temporally coordinated
release of multiple factors (Dimitriou et al, 2005). Studies in
humans and mice of the fracture hematoma, which is rich in these
factors and immune cells, suggest that the early inflammatory
events following fracture are critical to the outcome of fracture
healing (Grundnes & Reikeras, 1993; Chung et al, 2006; Kolar
et al, 2010, 2011; Hoff et al, 2013). Furthermore, the use of anti-
inflammatory or cytotoxic medications, including corticosteroids,
non-steroidal anti-inflammatory drugs, or chemotherapeutic agents,
during the early stages of fracture healing have been shown to be
deleterious (Sudmann et al, 1979; Engesaeter et al, 1992; Altman
et al, 1995; Gerstenfeld et al, 2003b; Simon & O’Connor, 2007;
Dimmen et al, 2008; Pountos et al, 2008). While these studies
support the importance of the early inflammatory events in deter-
mining the final outcome of fracture healing, the precise cells and
cytokines involved remain unclear.
Inflammation is necessary to initiate the reparative response
following injury (Nathan, 2006; Soehnlein & Lindbom, 2010). We
have previously found that proinflammatory cytokines, in particular
TNF, play an important role in fracture healing through the recruit-
ment and osteogenic differentiation of muscle-derived mesenchymal
stromal cells (MSCs) (Glass et al, 2011). In the skeletally mature
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Figure 4. Effects of inhibiting inflammatory cell recruitment on fracture healing.
Treatment with CCR2 antagonist, INCB3344, led to impaired fracture healing compared to vehicle control as shown by the reduced % callus mineralization at day 28 after
operation. Data are presented as mean  SEM. *P = 0.011 unpaired two-sided t-test. Representative micro-CT images are shown. Scale bar, 2 mm.
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animal, the contribution of the periosteum to fracture healing dimin-
ishes as the cambium layer regresses and loses it osteogenic activity
(O’Driscoll et al, 2001). In our fracture model, the periosteum is
stripped to ensure that fracture healing occurs by endochondral
healing as seen in the adult human, particularly in high-energy frac-
tures where the periosteum is often stripped and muscle is likely a
major contributor of osteoprogenitors (Liu et al, 2010; Chan et al,
2012b). Others have confirmed that TNF also promotes osteogenic
differentiation of bone marrow-derived MSCs in a time- and dose-
dependent manner (Mountziaris et al, 2010; Lu et al, 2012). In the
present study, we found that local TNF treatment was only effective
in augmenting fracture healing when administered at the fracture
site during the first 24 h after surgery (Fig 1B). Crucially, this indi-
cates that the early inflammatory phase represents a key rate-
controlling step in fracture healing. It is noteworthy and important
that this early phase typically coincides with the timing of surgical
treatment, which would therefore be a great advantage for potential
biologic treatments targeting early inflammation post-fracture.
Chronically high levels of TNF are known to impair fracture healing
(Alblowi et al, 2009). It is interesting to note that the highest dose
of TNF in the early inflammatory window did not do so. This may
be due to the relatively short stimulation period of osteoclasts. Our
current data indicate that rhTNF also plays an important role in
augmenting the early inflammatory response. In TNFR-deficient
mice, fracture healing was delayed particularly during the early
phase (Gerstenfeld et al, 2003a). Our gain and loss studies in which
exogenous TNF is administered and endogenous TNF expression is
depleted in wild-type animals confirm the role of TNF in fracture
healing as anti-TNF treatment delayed healing for at least 4 weeks.
Injury activates the innate immune response with recruitment of
neutrophils that mount a host defensive response, including phago-
cytosis and the release of reactive oxygen species, antimicrobial
peptides, and serine proteinases (Soehnlein & Lindbom, 2010).
Neutrophils are the most abundant leukocyte subset in the blood of
humans and mice. While neutrophils have traditionally been
regarded as professional phagocytes which clear debris and bacterial
pathogens and delay healing, evidence is emerging to support a
much wider role in orchestrating downstream events (Weiss, 1989;
Nathan, 2006; Bastian et al, 2011). Indeed, wounds heal poorly in
patients with insufficient neutrophils (Lekstrom-Himes & Gallin,
2000), or patients whose neutrophils are unable to adhere to the
endothelium or extracellular matrix (Kong et al, 1992; Roos & Law,
2001). While depletion of neutrophils led to a reduction of mesen-
chymal repair tissue within the injured growth plate cartilage in a
rat model (Chung et al, 2006), the role of neutrophils in bone heal-
ing is currently poorly understood. We found that depletion of
neutrophils by anti-Ly6G led to impairment of fracture healing
(Fig 2D and E) and that this may in part be due to disruption of the
downstream events of the inflammatory cascade, including recruit-
ment of monocytes (Fig 3A).
Previous studies have reported that neutrophils are able to
express TNF and that murine neutrophils contain pre-formed TNF
that is rapidly (15 min) mobilized to the cell surface upon cell acti-
vation (Bennouna & Denkers, 2005). However, the role of early
neutrophil-derived TNF in the inflammatory response is unknown
(Bennouna et al, 2003; Tsuda et al, 2004; van Gisbergen et al,
2005). Local expression of TNF is essential for the recruitment of
leukocytes to extravascular sites (Tessier et al, 1997). In vitro, TNF
promotes the release of chemokines, including CCL3 (MIP-1a) and
sIL-6R, the main neutrophil-derived chemokines responsible for
monocyte recruitment (Soehnlein & Lindbom, 2010), as well as
CCL2 (MCP-1) (Yamashiro et al, 2000). These drive the local
recruitment of other inflammatory cells, including monocytes and
macrophages (Pliyev, 2008), which are critical for bone repair
(Alexander et al, 2011). Although compared to monocytes or macro-
phages, each neutrophil produces lower levels of a given cytokine,
neutrophils typically represent the earliest cell type present and
greatly outnumber other phagocytes at inflammatory sites, by 1–2
orders of magnitude. Hence, they constitute a very important source
of cytokines, including TNF, at a critical juncture of the healing
response.
Although CCL2 was originally named “monocyte chemoattrac-
tant protein-1” (MCP-1), it has also been shown to be important in
the recruitment of neutrophils (Matsukawa et al, 1999; Speyer et al,
2004) as well as of monocytes and macrophages (Shi & Pamer,
2011), including at the fracture site (Xing et al, 2010). CCL2 is
produced by a number of cell types including neutrophils (Burn
et al, 1994; Yoshimura & Takahashi, 2007; Pliyev, 2008; Pelletier
et al, 2010) and monocytes (Yoshimura et al, 1989), as well as
endothelial cells (Hu et al, 2009), fibroblasts, vascular smooth
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Figure 5. TNF promotes fracture healing in osteoporotic bone.
rhTNF treatment augmented early phase fracture healing in osteoporotic mice. Treatment with 1 ng rhTNF at the fracture site on days 0 and 1 led to increased % callus
mineralization at day 14 but no difference at day 28 indicating accelerated early healing but the same final result at day 28. Data are presented as mean  SEM. At day 14,
PBS control versus TNF, **P = 0.0099; at day 28, PBS control versus TNF, nsP = 0.37, by unpaired two-sided t-test. Representative micro-CT images at day 14 are shown. rhTNF
treatment led to mature callus bridging across the fracture which was absent in the PBS-treated control group. Scale bar, 2 mm.
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muscle cells (Xing et al, 2007), and bone marrow cells (Cushing
et al, 1990; Moehle et al, 2011). It was detected within the first 24 h
following trauma in an in vitro fracture hematoma model (Hoff
et al, 2013). Despite reports that mRNA for CCL2 can been detected
in neutrophils (Burn et al, 1994; Yamashiro et al, 2000), it is
unknown whether human or murine neutrophils express the
protein. We found that addition of rhTNF to enriched bone marrow-
derived murine neutrophils exposed to fracture supernatant in vitro
led to increased levels of CCL2 by ELISA (Fig 3C). Notably, we were
also able to directly visualize murine neutrophils derived from bone
marrow readily expressing CCL2 protein by immunocytochemistry
when they were exposed to fracture supernatant and rhTNF but not
rhTNF alone (Supplementary Fig S1F). Our findings add to a previ-
ous report which demonstrated that TNF upregulated CCL2 mRNA
by human neutrophils in vitro when co-stimulated with TLR ligands
(Yamashiro et al, 2000). Our finding that both neutrophil depletion
and CCR2 antagonism lead to impaired fracture healing supports the
crucial role of neutrophil-derived CCL2 in fracture repair (Figs 2D, E
and 4).
Our observation that addition of TNF led to enhanced monocyte/
macrophage recruitment is notable as this cellular subset has been
implicated in osteogenesis (Guihard et al, 2012; Nicolaidou et al,
2012) and fracture callus remodeling (Alexander et al, 2011).
Recently, a population of macrophage-like cells, or “osteomacs”,
that line the bone surface osteoblasts have been described in both
mice and humans. These cells promote osteoblast mineralization
in vitro and are critical in the maintenance of mature osteoblasts
in vivo (Chang et al, 2008) as well as bone formation in a murine
model of bone injury (Alexander et al, 2011). Depletion of “osteo-
macs” led to concurrent reduction in the number of osteoblasts.
Although “osteomacs” are derived from the myeloid lineage, they
are distinct from multinucleated osteoclasts and it is likely that their
precursor cells diverge from a common progenitor earlier in the
myeloid lineage and mature along independent pathways to perform
different functional roles. “Osteomacs” therefore contribute to the
regulation of bone formation that is unrelated to osteoclastic bone
resorptive activity. However, how the prevailing cytokine environ-
ment affects the osteogenic activity of “osteomacs” remains to be
elucidated.
We previously found that exposure to rhTNF enhanced CCL2-
mediated recruitment of osteogenic precursor cells (Glass et al,
2011). Up-regulation of the CCL2/CCR2 axis has also been shown to
promote healing in various types of tissue, including skeletal
muscle, lung, and endothelium as well as bone through the recruit-
ment of monocytes/macrophages and MSCs (Weber et al, 1999;
Martinez et al, 2010; Lu et al, 2011; Arefieva et al, 2012; Chan et al,
2012a; Chen et al, 2012; Liang et al, 2012; Suresh et al, 2012; Wan
et al, 2012; Kostarnoy et al, 2013). CCR2-deficient mice exhibited
impaired healing in a closed fracture model (Xing et al, 2010).
However, genetically modified mice such as the osteopontin-
deficient mice often display subtle skeletal phenotypes due to func-
tional redundancy in gene family members (Davey et al, 2004) that
may influence the interpretation of data on complex physiological
processes such as fracture healing. Our finding that CCR2 inhibition
using a small molecule inhibitor impairs healing confirms the
importance of the CCL2/CCR2 axis (Fig 4). It is notable that CCR2
inhibition led to the greatest impairment of healing in our fracture
model, and showed a tendency toward non-union, a complication
that particularly affects open tibial fractures in patients. Non-union
is a failure of fracture repair and is characterized by the absence of
fracture callus formation with no bridging across the fracture gap
(Marsh, 1998). Clinically, this typically requires further operative
procedures to stimulate healing including excision of the intervening
fibrous tissue and juxtaposition of the surgically “freshened” bone
ends, which may in effect serve to “reset” the biological clock
through a controlled inflammatory insult. INCB3344 has been
shown to be a highly selective (> 100-fold) inhibitor for CCR2
compared to the closest related chemokine receptor subtypes,
including CCR1 and CCR5, and hence has limited off-target effects
(Xue et al, 2010). CCR2 has been shown to be crucial in the recruit-
ment of macrophages to sites of injury, and the movement of mono-
cytes from the bone marrow into the bloodstream and site of
traumatic injury (Kuziel et al, 1997; Ma et al, 2002; Schober et al,
2004; Tsou et al, 2007). However, monocytes and macrophages also
contribute to other aspects of fracture healing including the expres-
sion of osteogenic cytokines such as TNF and IL-6 (Yang et al, 2007;
Mountziaris et al, 2010; Glass et al, 2011; Lu et al, 2012), and osteo-
inductive growth factors such as BMP-2 (Champagne et al, 2002) as
well as osteoprogenitor differentiation, osteoclast differentiation,
and vasculogenesis (Xing et al, 2010). Therefore, it is possible that
the drastic impairment of fracture repair is a consequence of the
disruption of multiple CCR2-dependent processes. In our model, the
local addition of rmCCL2 did not augment fracture repair (Fig 1G),
but this may be due to a number of reasons, including the
short half-life of the protein and low bioavailability of the protein
(Ruggiero et al, 2003). Strategies to prolong the half-life of CCL2
including PEGylation, fusion proteins, antibody complexes, and
mutagenesis may be utilized to further test the therapeutic potential
of up-regulating CCL2.
Osteoporosis is characterized by low bone mass and weakened
bone structure, leading to 1.5 million fragility fractures in the USA
every year (Holroyd et al, 2008). Half of all patients who sustain
fragility fractures involving the femoral neck are permanently
disabled, and the mortality rate is 21–36% within the first year
(Eisman et al, 2012). Hence, there remains a pressing need to develop
effective strategies to accelerate healing of fragility fractures. To this
end, we examined whether TNF treatment would also be effective
in mice that have been rendered osteoporotic by oophorectomy. We
found a 40% improvement in healing at 2 weeks and equivalent
mineralization to PBS controls at 4 weeks (Fig 5). Rates of recovery
and mobilization in patients with fragility fractures are critically
dependent on fracture healing as premature loading leads to implant
failure, accounting for the excessive morbidity and mortality seen in
this vulnerable group of patients. Therefore, acceleration of healing
during the early phase of fracture repair is particularly relevant in
the clinical setting.
In summary, our combined in vivo and in vitro data show that
addition of low-dose rhTNF during the early inflammatory response
promotes the recruitment of neutrophils and monocytes via up-
regulation of CCL2 and leads to acceleration of fracture repair. Our
data show that the role of neutrophils is not simply limited to
clearance of pathogens and cellular debris. They also orchestrate the
next stage of resolution and regeneration through the recruitment of
monocytes. Mechanistically our data suggest that local administra-
tion of a low dose of recombinant TNF at the fracture site shortly
after injury acts via two mechanisms. Firstly, it potentiates and
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augments the early innate immune response comprising neutrophils
followed by monocyte/macrophage recruitment to promote the
physiological healing processes through the CCL2/CCR2 axis
(Fig 6). Secondly, it promotes the recruitment and osteogenic differ-
entiation of MSCs (Glass et al, 2011).
This study has a number of limitations. First, we used percentage
callus mineralization as the main parameter of fracture repair.
While biomechanical testing is considered as an alternative gold
standard in the assessment of bone quality, this is most reliable in
larger bones, such as femora of rats. Bend testing is used routinely
for intact bones, but we have found bend testing to be inconsistent
when testing the effects of biological therapies on fractured mouse
tibiae. Indeed, analysis of micro-CT parameters has been shown to
be a more sensitive method of evaluating murine fracture callus
properties than biomechanical studies (O’Neill et al, 2012). The
total and mineralized callus volumes from which the percentage
callus mineralization values were derived are shown in Supplemen-
tary Fig S2. Second, while our data show either augmentation or
impairment of fracture healing at either day 14 or day 28 post-
fracture, it is not possible to comment on whether the changes
observed are due to a change in the rate or quality of fracture repair,
or indeed both. This is because the mice were sacrificed at each time
point. For future investigation, in vivo micro-CT imaging would
enable us to follow the progression of fracture repair longitudinally
over time, with the advantage that each mouse will serve as its own
control to allow matched analyses.
By systematically unraveling the initial events in the fracture-
healing pathway, we have identified the potential of enhancing the
early innate immune response following fracture to augment frac-
ture repair. This has profound implications in the clinical setting.
For example, during surgical treatment of fractures, especially open
fractures, surgeons often lavage the wound extensively in order to
reduce the risk of infection, but also unintentionally deplete the
wound bed of crucial mediators as well as immune and osteopro-
genitor cells. Therapeutic up-regulation of the innate immune
system may be especially relevant under these circumstances.
However, of greatest potential clinical significance is the efficacy of
this novel regenerative therapy in osteoporotic bone, the major
unmet clinical need.
Materials and Methods
Murine fracture model
Animal fracture model procedures were approved by the institu-
tional ethics committee and the United Kingdom Home Office (PLL
71/7161). Skeletally mature (12–14 week old) female C57/BL6 mice
were obtained from Charles River, UK. Normal chow and drinking
water were provided ad libitum. The murine fracture procedure
was performed as previously described (Harry et al, 2008). Briefly,
an incision is made over the tibia. The periosteum is stripped
Early inflammatory pathway in fracture repair
TNF
Figure 6. Definition of the early fracture healing pathway.
Schematic detailing the role of the early inflammatory pathway in fracture healing. Addition of local rhTNF promotes the recruitment of neutrophils and monocytes via
up-regulation of CCL2, leading to augmentation of fracture repair.
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circumferentially, the medullary canal is reamed, and a 0.38-mm
intramedullary fixation pin is inserted. An osteotomy is created at
the junction of the middle and distal thirds of the tibia and the fixa-
tion pin cut flush with the tibial cortex and skin closed directly with
non-absorbable sutures.
Anti-TNF: TN3-19.12, a neutralizing hamster IgG1 anti-TNF-a/b
mAb (Leinco Technologies) or IgG control was given (1 mg) via
intraperitoneal injections on days 0, 2, 5, and 8 after operation.
rmIL10 (R&D Systems) was injected locally at the fractures site at
10 ng on days 0 and 1; PBS was used as vehicle control.
Anti-IL10R or IgG isotype control (R&D Systems) was given
(2 lg) via intraperitoneal injections on day 1 before operation and
days 0, 1, 4, 6, and 8 after operation.
Anti-Ly6G-specific monoclonal antibody, 1A8, or IgG2A isotype
control, 2A3 (BioXCell) (Daley et al, 2008), was given (0.5 mg) via
intraperitoneal injections on days 1 and 3 before and after operation.
The CCR2 antagonist, INCB3344 (Brodmerkel et al, 2005; Shin
et al, 2009; Xue et al, 2010; Xie et al, 2011; Chan et al, 2012a), was
administered at 30 mg/kg/day via daily intraperitoneal injections
starting 3 h before operation and continuing until and including day
8 after operation (Haoyuan Chemexpress Co Ltd). Vehicle control
was 10% DMSO/0.9% carboxymethylcellulose.
rmCCL2 (R&D Systems) was injected locally at the fracture site
10 ng or 100 ng on day 0 and day 1; PBS was used as vehicle control.
Fig 1A: TNF 0 ng (n = 8), 0.01 ng (n = 7), 1 ng (n = 6), 100 ng
(n = 8)
Fig 1B: Ctrl (n = 9), D0+ 1 (n = 6), D0 (n = 10), D1 (n = 7),
D2 (n = 8), D3 (n = 6)
Fig 1C: Ctrl (n = 10), anti-TNF (n = 6), rmIL-10 (n = 8)
Fig 2A: Ctrl (n = 6), 0.25 (n = 6), 0.5 (n = 12), 1 (n = 9),
3 (n = 10), 6 (n = 6), 12 (n = 6), 24 (n = 10), 72 (n = 6)
Fig 2B (left): IgG ctrl (n = 8), Anti-Ly6G (n = 9); (right) n = 3
per group
Fig 2E: IgG Ctrl (n = 8), Anti-Ly6G (n = 9)
Fig 3A: (n = 3) per group
Fig 3B: media (n = 11) media+ TNF (n = 12), FS (n = 8),
FS + TNF (n = 11), FS + TNF + anti-CCL2 (n = 8), FS +
TNF + IgG (n = 8)
Fig 3C: media (n = 6), media+ TNF (n = 6), FS (n = 6), FS +
TNF (n = 6)
Fig 3D: n = 3 per group
Fig 4: vehicle (n = 6), CCR2 antagonist (n = 7)
Fig 5: Day 14 PBS (n = 6), TNF (n = 6), Day 28 PBS (n = 7),
TNF (n = 7)
Micro-CT scanning and analysis
Mouse tibiae were harvested at 14 or 28 days post-fracture and fixed
in 70% ethanol. Each bone was scanned with a Skyscan 1174
scanner (SkyScan, Kontich, Belgium), 50 kV, 800 lA, and 8.3 lm
isometric voxel resolution, and 0.7 degree rotation step. Bones
exhibiting angulation, rotation, or hypertrophic non-union were
excluded. Scans were analyzed using SkyScan CTAnalyser software,
version 1.9.3.0 (SkyScan, Kontich, Belgium). Each bone was
analyzed by selecting a volume of interest commencing at the frac-
ture site and proceeding proximally for 363 slices (3 mm in height).
This region was selected to avoid potential confounding effects of
the fibula. Total callus volume was delineated from surrounding
tissues and the original bone of the tibia using hand-contoured
regions of interest. Mineralized callus volume was determined using
global thresholding at a density range calibrated to bone mineral
density of 350 gm/cm3, as previously described (Harry et al, 2008).
Percent callus mineralization was calculated as mineralized callus
volume divided by total callus volume and normalized against
vehicle (PBS) or IgG isotype control.
In situ hybridization
Murine lower limbs were fixed in 4% paraformaldehyde overnight
and decalcified for 6 weeks in a 50% mixture of 20% EDTA and 4%
paraformaldehyde. Care was taken during processing and section
cutting to avoid RNase contamination.
Specific localization of Tnf mRNA was accomplished by in situ
hybridization using an antisense riboprobe synthesized with T7 RNA
polymerase using 35S-UTP (~800 Ci/mmol; Perkin Elmer UK) and
IMAGE clone 40126376 (Source BioScience UK) containing the
sequence of interest. A clone was grown in the presence of kanamy-
cin, purified using a Qiagen maxi prep kit, and the resultant plasmid
linearized with SpeI to prepare a template that made a 768 base anti-
sense riboprobe that was used without hydrolysis. The region of
sequence used to produce the riboprobe did not show significant
homology to any other known mouse mRNA sequences in the RefSeq.
The methods for pre-treatment, hybridization, washing, and
dipping of slides in Ilford K5 for autoradiography were performed as
previously described (Steddon & Cunningham, 2005) for formalin-
fixed paraffin-embedded tissue with some modifications (Fromigue
et al, 2009).
The presence of hybridizable mRNA in all compartments of the
tissues studied was established in near serial sections using an anti-
sense b-actin probe. Autoradiography was carried out at 4°C (two
exposures per section at 8 and 15 days) before developing in Kodak
D19 and counterstaining by Giemsa’s method. Sections were
examined under conventional or reflected light dark-field conditions
(Nikon Eclipse ME600 epi-illumination microscope with Q imaging
MicroPublisher 5.0 camera) that allowed individual autoradiographic
silver grains to be seen as bright objects on a dark background.
Immunohistochemistry
Monocytes/macrophages: Limbs were fixed in 4% paraformalde-
hyde overnight and decalcified for 6 weeks in 15% EDTA. The
limbs were bisected longitudinally and paraffin-embedded, and
4-lm sections were cut. Immunohistochemistry (IHC) was
performed on deparaffinized and rehydrated sections, with specific
primary antibody against F4/80 (rat anti-mouse (Biolegends)), as
previously described (Alexander et al, 2011), or anti-neutrophil
elastase (Abcam). All sections were counterstained using Mayer’s
haematoxylin (Leica Biosystems, UK). Tissue staining was viewed
using an Olympus BX51 microscope with an Olympus DP71 camera
and DP Manager (Olympus) imaging software.
Quantification of circulating neutrophils
Mice were anaesthetized with pentobarbital until unresponsive to
stimuli, and a cardiac puncture was performed. Blood was collected
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into a syringe containing 100 ll sodium citrate. Blood smears were
stained with DiffQuik for the enumeration of neutrophils and mono-
nuclear cells. Six animals were used per time point.
Murine fracture supernatant
C57BL/6 mice were anaesthetized, and closed fractures were
created in the lower limbs. Mice are culled at 3 h post-operatively,
and the fractured bone segments are harvested and incubated in
serum-free DMEM + 1% penicillin/streptomycin for 16 h. Cytokine
levels were measured using a pro-inflammatory 7-plex plate and a
SECTOR Imager 2400 reader (Mesoscale Discovery).
Air pouch experiments
Ten- to 12-week C57BL/6 female mice (Charles River, UK) were
used. Air pouch model procedures were approved by the institu-
tional ethics committee and the United Kingdom Home Office (PLL
70/7335). Air pouches were produced as previously described
(Vestergaard et al, 2005; Wilting et al, 2007; Mosekilde et al, 2011)
on the dorsum of the mice by subcutaneous injection of 5 ml sterile
air on day 0 and 2 ml on day 4. On day 5, the animals were random-
ized into groups (minimum six animals per group) and the experi-
ment was conducted in a double-blinded manner. Air pouches were
injected with 400 ll of media, fracture supernatant, or fracture
supernatant and 1 ng of rhTNF. The animals were sacrificed, and
air pouches lavaged with 2 ml of PBS at 4 h post-injection. The
exudate was centrifuged at 1,500 for 5 min, and pellets containing
the migrated cells were re-suspended in fresh PBS for counting using
a hematocytometer following red cell lysis treatment. Characteriza-
tion of leukocyte subpopulations migrating into the pouch space
was determined by flow-cytometry staining with Ly-6G PE (clone
1A8, Miltenyi Biotec, UK), CD11b FITC (clone M1/70, eBioscience,
UK) and CD115 APC (clone AFS98, eBioscience, UK) antibodies.
PMNs were identified as Ly-6G+, CD11b+ cells, while the monocytic
cells were identified as Ly-6G, CD11b+, and CD115+ cells as
described previously (Vestergaard et al, 2005). The levels of mCCL2
cytokine in the exudates were analyzed with a SECTOR Imager 2400
reader (Mesoscale Discovery).
In vitro neutrophil experiment
Neutrophils are enriched to 82.7% purity (Supplementary Fig S1E)
using a neutrophil isolation kit according to manufacturer’s instruc-
tions (Stem Cell Technology) and incubated in 180 ll murine frac-
ture supernatant + 10% FCS + 1% penicillin/streptomycin at 37°C,
4% CO2, and a density of 275,000 cells per well in a 96-well plate.
rhTNF or PBS (in 20 ll) is added at 30 min. Cells and supernatants
are harvested at 1 h. Protein levels of mCCL2 cytokine in the
supernatants were analyzed as described above. Experiments were
performed in triplicates.
Immunocytochemistry
Bone marrow cells are extracted from murine tibiae under sterile
conditions. The cells are washed, centrifuged, and suspended at
200,000 cells per ml. They were plated on glass coverslips and then
exposed to either media + rhTNF at 1 ng/ml (control) or fracture
supernatant + rhTNF at 1 ng/ml (treatment). After 4 h, cells were
fixed with 4% paraformaldehyde in PBS for 15 min at 37°C,
quenched with 50 mM NH4Cl/PBS for 10 min, and permeabilized
with 0.1% Triton X-100 in PBS for 5 min. Samples were blocked
with 3% BSA in PBS for 30 min at room temperature followed by
incubation with rabbit anti-neutrophil elastase and rat anti-CCL2
diluted in 3% BSA in PBS for 1 h at room temperature. After wash-
ing steps, staining with the appropriate secondary antibody was
performed. Neutrophil elastase staining was performed with Alexa
Fluor 488, CCL2 was stained with Alexa Fluor 594, and the nucleus
was stained with DAPI. Samples were mounted with ProGold anti-
fade mounting media and imaged with a fluorescence microscope.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 6
(GraphPad software, San Diego, CA). For every figure, statistical
tests are justified as appropriate. All data were expressed as
mean  standard error of the mean (SEM). The significance of the
The paper explained
Problem
Bone factures are very common. While the majority heal uneventfully,
certain sub-groups would benefit from strategies to accelerate healing.
These include high-energy open fractures, which are limb-threatening
injuries prone to delayed and non-union, and fragility fractures in
osteoporotic bone. The rates of recovery and mobilization are limited
by the fracture healing time in patients with fragility fractures, thus
accounting for the excessive morbidity and mortality seen in this
vulnerable group of patients. There is currently no approved therapy
for accelerating healing of fragility fractures.
Results
Using a combined in vivo and in vitro approach, we demonstrate the
importance of the early innate inflammatory response in the healing
of bone fractures. Local administration of TNF, a pro-inflammatory
cytokine, within 24 h of injury accelerates fracture repair in vivo.
Conversely, administration of either anti-TNF or rm-IL-10, an anti-
inflammatory cytokine, impairs fracture healing. TNF is expressed by
both neutrophils and monocytes/macrophages following fracture.
Addition of recombinant TNF to the fracture environment up-regulates
the innate immune response by promoting the recruitment of
neutrophils followed by monocyte/macrophages, the latter through the
up-regulation of the monocyte chemoattractant, CCL2. Depletion of
neutrophils impairs fracture repair in vivo. While the production of
CCL2 by neutrophils is controversial in the literature, we demonstrate
enhanced expression of CCL2 in neutrophils exposed to fracture envi-
ronment following addition of TNF using immunocytochemistry.
Macrophages are known to play a key role in orchestrating endochon-
dral bone repair. Inhibition of CCR2, the main receptor for CCL2, found
on monocytes/macrophages, led to significant impairment of fracture
repair in vivo. These data demonstrate the role of the innate immune
response via the TNF/CCL2/CCR2 axis in fracture repair.
Impact
This is the first direct evidence on the importance of the innate
immune response in fracture healing and how it may be targeted to
accelerate fracture repair. Our observation that this strategy pertains
to osteoporotic bone in vivo is of particular interest as clinical transla-
tion would address one of the major unmet medical needs of the 21st
century.
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difference between two groups was determined with a one- or two-
sided unpaired t-tests. Multiple comparisons were made using one-
way analyses of variance (ANOVA) followed by Bonferroni or
Dunnett post-test analysis for multiple groups. Exact P-values are
provided for t-tests, and multiplicity-adjusted P-values are provided
for multiple comparisons. P < 0.05 are considered statistically
significant. Significant results are expressed using asterisks, where
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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